FTC Loses Appeal in Androgel ‘Pay-for-Delay’ Patent Case

A U.S. appeals court handed the Federal Trade Commission a defeat in its campaign to block so-called pay-for-delay arrangements between brand-name and generic drug makers, ruling a settlement involving a patent on Androgel didn’t violate antitrust laws.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.